ArticleAddiction & health2026
Cognitive Impairments in Substance Use Patients Treated with Methadone.
Article in Addiction & health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Substance abuse remains a critical global challenge with social, economic, and health impacts. Cognitive impairments are recognized as significant risk factors for relapse and poor treatment outcomes in individuals undergoing substance abuse treatment. This study investigated the prevalence of cognitive impairments and associated factors among patients receiving methadone maintenance therapy (MMT). Methods: A cross-sectional analytical study was conducted among 370 patients receiving MMT at substance abuse treatment centers in Rasht in 2022. Participants were selected through a two-stage cluster sampling method after obtaining informed consent. Data were collected using demographic questionnaires, the Depression, Anxiety, and Stress Scale-21 (DASS-21), and the Montreal Cognitive Assessment (MoCA). Statistical analyses, including standard deviation, Spearman's correlation, and the Kruskal-Wallis test, were conducted using SPSS version 21 ( Results: Cognitive impairments were observed in 11.1% of participants, with an average age of 49.58±14.40 years. Male participants scored significantly higher on the verbal fluency ( Conclusion: Cognitive impairments were identified in 11.1% of participants. Longer durations of primary substance use, higher methadone maintenance doses, and extended treatment durations were significantly associated with poorer cognitive performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.